中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
1期
63-65
,共3页
段玉龙%刘擎国%范向辉%赵诚%解洪泉%姬国强
段玉龍%劉擎國%範嚮輝%趙誠%解洪泉%姬國彊
단옥룡%류경국%범향휘%조성%해홍천%희국강
小细胞肺癌%化学疗法%放射疗法%综合治疗%预后
小細胞肺癌%化學療法%放射療法%綜閤治療%預後
소세포폐암%화학요법%방사요법%종합치료%예후
Small -cell lung cancer%Chemotherapy%Radiotherapy%Comprehensive treatment%Prognosis
目的 探讨化疗联合放疗治疗局限期小细胞肺癌(SCLC)的疗效.方法 将89例符合条件的局限期SCLC患者随机分为化放交替组和化放序贯组.所有患者均行EP方案化疗:顺铂40 mg/d,第1～3天静脉滴注;依托泊昔100 mg/d,第1～5天静脉滴注.3周为1个周期,共化疗4～6个周期.放疗常规分割,DT 56～60 Gy.结果 交替组与序贯组完全缓解(CR)率、部分缓解率、有效率分别为38%、51%、89%和23%、61%、84%(P>0.05);局部复发率和远处转移率分别为18%、23%和21%、30%(P>0.05),1、2、3年生存率两组分别为71%、38%、17%和67%、31%、15%(P>0.05).两组Ⅱ+Ⅲa病例的CR率、2年生存率分别为65%和33%、52%和39%(P<0.05).结论 化疗联合放疗治疗局限期SCLC近期效果满意,化放交替组和化放序贯组疗效差异无统计学意义,但TNM分期可能为影响预后的因子.
目的 探討化療聯閤放療治療跼限期小細胞肺癌(SCLC)的療效.方法 將89例符閤條件的跼限期SCLC患者隨機分為化放交替組和化放序貫組.所有患者均行EP方案化療:順鉑40 mg/d,第1～3天靜脈滴註;依託泊昔100 mg/d,第1～5天靜脈滴註.3週為1箇週期,共化療4～6箇週期.放療常規分割,DT 56～60 Gy.結果 交替組與序貫組完全緩解(CR)率、部分緩解率、有效率分彆為38%、51%、89%和23%、61%、84%(P>0.05);跼部複髮率和遠處轉移率分彆為18%、23%和21%、30%(P>0.05),1、2、3年生存率兩組分彆為71%、38%、17%和67%、31%、15%(P>0.05).兩組Ⅱ+Ⅲa病例的CR率、2年生存率分彆為65%和33%、52%和39%(P<0.05).結論 化療聯閤放療治療跼限期SCLC近期效果滿意,化放交替組和化放序貫組療效差異無統計學意義,但TNM分期可能為影響預後的因子.
목적 탐토화료연합방료치료국한기소세포폐암(SCLC)적료효.방법 장89례부합조건적국한기SCLC환자수궤분위화방교체조화화방서관조.소유환자균행EP방안화료:순박40 mg/d,제1～3천정맥적주;의탁박석100 mg/d,제1～5천정맥적주.3주위1개주기,공화료4～6개주기.방료상규분할,DT 56～60 Gy.결과 교체조여서관조완전완해(CR)솔、부분완해솔、유효솔분별위38%、51%、89%화23%、61%、84%(P>0.05);국부복발솔화원처전이솔분별위18%、23%화21%、30%(P>0.05),1、2、3년생존솔량조분별위71%、38%、17%화67%、31%、15%(P>0.05).량조Ⅱ+Ⅲa병례적CR솔、2년생존솔분별위65%화33%、52%화39%(P<0.05).결론 화료연합방료치료국한기SCLC근기효과만의,화방교체조화화방서관조료효차이무통계학의의,단TNM분기가능위영향예후적인자.
Objective To evaluate of chemotherapy combined with radiotherapy in the treatment of limited - stage small - cell lung cancer ( LD - SCLC ). Methods Eighty - nine patients with LD -SCLC were randmized into interdigitatiag chemoradiotherapy group and sequential chemoradiotherapy group. All patients received four to six cycles of alternating EP( P:cisplatin 40 mg d1-3 ,E:etoposide 100 mg d1-5 )chemotherapy, three weeks for a cycle, All patients also received thoracic radiotherapy with conventional fraction ,2.0 Gy per fraction, five fractions per week. The total dose was 56 -60 Gy. Results Interdigitating chemoradiotherapy group and sequential chemoradiotherapy group, CR were 38% and 23%, PR were 51% and 61%, CR + PR were 89% and 84%. Its frequenciesof local recurrence and distant metastasis were 18% ,23% and 21% ,30% (P > 0.05). The 1 - ,2 - ,3 -year survial rates were 71% ,38% ,17% and 67% ,31% ,15% (P >0. 05). The Ⅱ + Ⅲa patients of interdigitating chemoradiotherapy group and sequential ehemoradiotherapy group, CR was 65% and 33%, The 2 - year survial rates were 52% and 39% (P < 0.05 ). Conclusions The therapeutic effect of chemotherapy combined with radiotherapy for LD - SCLC was satisfing. There was no significant difference in the effect between the two groups, but TNM stage may be still a significante prognostic factor.
